A new look at the safety and tolerability of prostaglandin analogue eyedrops in glaucoma and ocular hypertension

Katsanos, Andreas; Riva, Ivano; Bozkurt, Banu; Holló, Gábor; Quaranta, Luciano; Oddone, Francesco; İrkeç, Murat; Dutton, Gordon N.; Konstas, Anastasios G. P.

doi:10.1080/14740338.2022.1996560

Cited by 12 publications

(4 citation statements)

References 135 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Iris pigmentation appears to be irreversible, whereas changes in eyelash and periocular skin pigmentation are reversible within a few months after stopping the drug. [ 2 , 47 ] Also, discontinuation of the medication results in partial or complete reversal of DUES in 3–6 months. [ 48 ]…”

Section: Prostaglandinsmentioning

confidence: 99%

“…Among these classes, PGAs are widely used as the first line of drug in the management of primary open-angle glaucoma (POAG) and ocular hypertension (OHT). [ 2 - 4 ] The European Glaucoma Society and the Asia-Pacific Glaucoma Society guidelines and various other guidelines recommend PGA as the first line of drug in the management of glaucoma because of their efficacy, low risk of systemic side effects, and convenient once-daily dosing. [ 5 - 7 ] This article aims to review the evidence on the currently available PGAs in ophthalmic practice.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Prostaglandin analogs in ophthalmology

Subbulakshmi

Srinivasan

Venkatesh

2023

Indian Journal of Ophthalmology

View full text Add to dashboard Cite

Glaucoma is a major cause of irreversible blindness worldwide. Reducing intraocular pressure (IOP) is currently the only approach to prevent further optic nerve head damage. Pharmacotherapy is the mainstay of treatment for glaucoma patients. In recent years, a significant milestone in glaucoma treatment has been a transition to prostaglandin analogs (PGAs) as the first line of drugs. The rapid shift from traditional β-blockers to PGAs is primarily due to their excellent efficacy, convenient once-a-day usage, better diurnal control of IOP, and systemic safety profiles. This review article aims to provide information regarding the various PGAs in practice and also the newer promising drugs.

show abstract

Section: Prostaglandinsmentioning

confidence: 99%

mentioning

confidence: 99%

Prostaglandin analogs in ophthalmology

Subbulakshmi

Srinivasan

Venkatesh

2023

Indian Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…Хотя краткосрочная эффективность и безопасность АПГ широко исследовалась, меньше известно об их долгосрочной безопасности и переносимости. [9].…”

Section: Advanced Ophthalmologyunclassified

Исследование Ишемического Состояния Зоны Лимба У Пациентов С Первичной Открытоугольной Глаукомой При Терапии Аналогами Простагландинов

Гарькавенко¹,

Гайделис²,

Балашова³

2023

View full text Add to dashboard Cite

Цель исследования. Провести сравнительную оценку спектрофлуориметрических показателей зоны лимба при лечении пациентов с первичной открытоугольной глаукомы аналогами простагландинов. Материалы и методы. Всего обследовано 129 пациента с ПОУГ в возрасте 58–87 лет, из них 30 (23%) пациентов с развитой стадией ПОУГ и 99 (77%) пациента с далеко зашедшей стадией, получавшие различные аналоги простагландинов в течение 1 месяца. Проведено спектрофлуориметрическое исследование зоны лимба как до лечения, так и после. Результаты. Спектрофлуориметрические показатели зоны лимба показывают, что все молекулы АПГ оказывают ишемическое воздействие на зону лимба. Применение бета-блокаторов вызывает минимальное влияние на ишемическое состояние зоны лимба. Заключение. Максимально выраженное ишемическое воздействие на зону лимба выявлено у пациентов, которые получали Биматопрост. Применение Латанопроста более эффективно и в меньшей степени влияет на ишемическое состояние зоны лимба. Перед назначением медикаментозного лечения спектрофлуориметрические показатели ишемии зоны лимба у пациентов с далекозашедшей стадией оказались выше, чем у пациентов с развитой стадией, что подтверждает более выраженный пролонгированный гипотензивный у пациентов после антиглаукомных операций в развитой стадии ПОУГ.

show abstract

“…It was discovered that PGs reduce the IOP by enhancing the aqueous humor outflow, and the first antiglaucoma prostaglandin analog (PGA), latanoprost, received the Food and Drug Administration’s approval between August 2000 and March 2001 [ 6 ]. Now PGAs are considered the drugs of choice for the treatment of POAG [ 7 , 8 ]. Currently there are five PGAs marketed as aqueous eye drops.…”

Section: Introductionmentioning

confidence: 99%

Aqueous Prostaglandin Eye Drop Formulations

Jansook

Loftsson

2022

Pharmaceutics

View full text Add to dashboard Cite

Glaucoma is one of the leading causes of irreversible blindness worldwide. It is characterized by progressive optic neuropathy in association with damage to the optic nerve head and, subsequently, visual loss if it is left untreated. Among the drug classes used for the long-term treatment of open-angle glaucoma, prostaglandin analogues (PGAs) are the first-line treatment and are available as marketed eye drop formulations for intraocular pressure (IOP) reduction by increasing the trabecular and uveoscleral outflow. PGAs have low aqueous solubility and are very unstable (i.e., hydrolysis) in aqueous solutions, which may hamper their ocular bioavailability and decrease their chemical stability. Additionally, treatment with PGA in conventional eye drops is associated with adverse effects, such as conjunctival hyperemia and trichiasis. It has been a very challenging for formulation scientists to develop stable aqueous eye drop formulations that increase the PGAs’ solubility and enhance their therapeutic efficacy while simultaneously lowering their ocular side effects. Here the physiochemical properties and chemical stabilities of the commercially available PGAs are reviewed, and the compositions of their eye drop formulations are discussed. Furthermore, the novel PGA formulations for glaucoma treatment are reviewed.

show abstract

A new look at the safety and tolerability of prostaglandin analogue eyedrops in glaucoma and ocular hypertension

Cited by 12 publications

References 135 publications

Prostaglandin analogs in ophthalmology

Prostaglandin analogs in ophthalmology

Исследование Ишемического Состояния Зоны Лимба У Пациентов С Первичной Открытоугольной Глаукомой При Терапии Аналогами Простагландинов

Aqueous Prostaglandin Eye Drop Formulations

Contact Info

Product

Resources

About